Nonoperative therapies for combined modality treatment of hepatocellular cancer

Expert consensus statement

Roderich E. Schwarz, Ghassan K. Abou-Alfa, Jeffrey F. Geschwind, Sunil Krishnan, Riad Salem, Alan P. Venook

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Although surgical resection and liver transplantation are the only treatment modalities that enable prolonged survival in patients with hepatocellular carcinoma (HCC), the majority of HCC patients presents with advanced disease and do not undergo resective or ablative therapy. Transarterial chemoembolization (TACE) is indicated in intermediate/advanced stage unresectable HCC even in the setting of portal vein involvement (excluding main portal vein). Sorafenib has been shown to improve survival of patients with advanced HCC in two controlled randomized trials. Yttrium 90 is a safe microembolization treatment that can be used as an alternative to TACE in patients with advanced liver only disease or in case of portal vein thrombosis. External beam radiation can be helpful to provide local control in selected unresectable HCC. These different treatment modalities may be combined in the treatment strategy of HCC and also used as a bridge to resection or liver transplantation. Patients should undergo formal multidisciplinary evaluation prior to initiating any such treatment in order to individualize the best available options.

Original languageEnglish (US)
Pages (from-to)313-320
Number of pages8
JournalHPB
Volume12
Issue number5
DOIs
StatePublished - Jun 2010

Fingerprint

Combined Modality Therapy
Liver Neoplasms
Hepatocellular Carcinoma
Portal Vein
Liver Transplantation
Therapeutics
Yttrium
Survival
Liver Diseases
Thrombosis
Randomized Controlled Trials
Radiation

Keywords

  • Chemoembolization
  • Chemotherapy
  • Consensus conference
  • Hepatocellular cancer
  • Hepatoma
  • Liver transplantation
  • Radiotherapy
  • Surgery

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Schwarz, R. E., Abou-Alfa, G. K., Geschwind, J. F., Krishnan, S., Salem, R., & Venook, A. P. (2010). Nonoperative therapies for combined modality treatment of hepatocellular cancer: Expert consensus statement. HPB, 12(5), 313-320. https://doi.org/10.1111/j.1477-2574.2010.00183.x

Nonoperative therapies for combined modality treatment of hepatocellular cancer : Expert consensus statement. / Schwarz, Roderich E.; Abou-Alfa, Ghassan K.; Geschwind, Jeffrey F.; Krishnan, Sunil; Salem, Riad; Venook, Alan P.

In: HPB, Vol. 12, No. 5, 06.2010, p. 313-320.

Research output: Contribution to journalArticle

Schwarz, RE, Abou-Alfa, GK, Geschwind, JF, Krishnan, S, Salem, R & Venook, AP 2010, 'Nonoperative therapies for combined modality treatment of hepatocellular cancer: Expert consensus statement', HPB, vol. 12, no. 5, pp. 313-320. https://doi.org/10.1111/j.1477-2574.2010.00183.x
Schwarz, Roderich E. ; Abou-Alfa, Ghassan K. ; Geschwind, Jeffrey F. ; Krishnan, Sunil ; Salem, Riad ; Venook, Alan P. / Nonoperative therapies for combined modality treatment of hepatocellular cancer : Expert consensus statement. In: HPB. 2010 ; Vol. 12, No. 5. pp. 313-320.
@article{5fca6b4aaf4847ce80eb090cccbbb66a,
title = "Nonoperative therapies for combined modality treatment of hepatocellular cancer: Expert consensus statement",
abstract = "Although surgical resection and liver transplantation are the only treatment modalities that enable prolonged survival in patients with hepatocellular carcinoma (HCC), the majority of HCC patients presents with advanced disease and do not undergo resective or ablative therapy. Transarterial chemoembolization (TACE) is indicated in intermediate/advanced stage unresectable HCC even in the setting of portal vein involvement (excluding main portal vein). Sorafenib has been shown to improve survival of patients with advanced HCC in two controlled randomized trials. Yttrium 90 is a safe microembolization treatment that can be used as an alternative to TACE in patients with advanced liver only disease or in case of portal vein thrombosis. External beam radiation can be helpful to provide local control in selected unresectable HCC. These different treatment modalities may be combined in the treatment strategy of HCC and also used as a bridge to resection or liver transplantation. Patients should undergo formal multidisciplinary evaluation prior to initiating any such treatment in order to individualize the best available options.",
keywords = "Chemoembolization, Chemotherapy, Consensus conference, Hepatocellular cancer, Hepatoma, Liver transplantation, Radiotherapy, Surgery",
author = "Schwarz, {Roderich E.} and Abou-Alfa, {Ghassan K.} and Geschwind, {Jeffrey F.} and Sunil Krishnan and Riad Salem and Venook, {Alan P.}",
year = "2010",
month = "6",
doi = "10.1111/j.1477-2574.2010.00183.x",
language = "English (US)",
volume = "12",
pages = "313--320",
journal = "HPB",
issn = "1365-182X",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - Nonoperative therapies for combined modality treatment of hepatocellular cancer

T2 - Expert consensus statement

AU - Schwarz, Roderich E.

AU - Abou-Alfa, Ghassan K.

AU - Geschwind, Jeffrey F.

AU - Krishnan, Sunil

AU - Salem, Riad

AU - Venook, Alan P.

PY - 2010/6

Y1 - 2010/6

N2 - Although surgical resection and liver transplantation are the only treatment modalities that enable prolonged survival in patients with hepatocellular carcinoma (HCC), the majority of HCC patients presents with advanced disease and do not undergo resective or ablative therapy. Transarterial chemoembolization (TACE) is indicated in intermediate/advanced stage unresectable HCC even in the setting of portal vein involvement (excluding main portal vein). Sorafenib has been shown to improve survival of patients with advanced HCC in two controlled randomized trials. Yttrium 90 is a safe microembolization treatment that can be used as an alternative to TACE in patients with advanced liver only disease or in case of portal vein thrombosis. External beam radiation can be helpful to provide local control in selected unresectable HCC. These different treatment modalities may be combined in the treatment strategy of HCC and also used as a bridge to resection or liver transplantation. Patients should undergo formal multidisciplinary evaluation prior to initiating any such treatment in order to individualize the best available options.

AB - Although surgical resection and liver transplantation are the only treatment modalities that enable prolonged survival in patients with hepatocellular carcinoma (HCC), the majority of HCC patients presents with advanced disease and do not undergo resective or ablative therapy. Transarterial chemoembolization (TACE) is indicated in intermediate/advanced stage unresectable HCC even in the setting of portal vein involvement (excluding main portal vein). Sorafenib has been shown to improve survival of patients with advanced HCC in two controlled randomized trials. Yttrium 90 is a safe microembolization treatment that can be used as an alternative to TACE in patients with advanced liver only disease or in case of portal vein thrombosis. External beam radiation can be helpful to provide local control in selected unresectable HCC. These different treatment modalities may be combined in the treatment strategy of HCC and also used as a bridge to resection or liver transplantation. Patients should undergo formal multidisciplinary evaluation prior to initiating any such treatment in order to individualize the best available options.

KW - Chemoembolization

KW - Chemotherapy

KW - Consensus conference

KW - Hepatocellular cancer

KW - Hepatoma

KW - Liver transplantation

KW - Radiotherapy

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=77953570290&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953570290&partnerID=8YFLogxK

U2 - 10.1111/j.1477-2574.2010.00183.x

DO - 10.1111/j.1477-2574.2010.00183.x

M3 - Article

VL - 12

SP - 313

EP - 320

JO - HPB

JF - HPB

SN - 1365-182X

IS - 5

ER -